We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.
- Authors
Bourrier, A.; Carrat, F.; Colombel, J.‐F.; Bouvier, A.‐M.; Abitbol, V.; Marteau, P.; Cosnes, J.; Simon, T.; Peyrin‐Biroulet, L.; Beaugerie, L.; Gendre, Jean‐Pierre; Lémann, Marc; Hébuterne, Xavier; Cortot, Antoine; Bouhnik, Yoram; Laharie, David; Dupas, Jean Louis; Flourié, Bernard; Lerebours, Eric; Allez, Matthieu
- Abstract
Background The risk of urinary tract cancers, including kidney and bladder cancers, was increased in transplant recipients receiving thiopurines. Aim To assess the risk of urinary tract cancers in patients with inflammatory bowel disease (IBD) receiving thiopurines in the CESAME observational cohort. Methods Between May 2004 and June 2005, 19 486 patients with IBD, 30.1% of whom were receiving thiopurines, were enrolled. Median follow-up was 35 months (IQR: 29-40). Results Ten and six patients developed respectively kidney and bladder cancer. The incidence rates of urinary tract cancer were 0.48/1000 patient-years in patients receiving thiopurines (95% CI: 0.21-0.95), 0.10/1000 patient-years in patients who discontinued thiopurines (95% CI: 0.00-0.56) and 0.30/1000 patient-years in patients never treated with thiopurines (95% CI: 0.12-0.62) at entry. The standardised incidence ratio of urinary tract cancer was 3.40 (95% CI: 1.47-6.71, P = 0.006) in patients receiving thiopurines, 0.64 (95% CI: 0.01-3.56, P = 0.92) in patients previously exposed to thiopurines and 1.17 (95% CI: 0.47-12.42, P = 0.78) in patients never treated with thiopurines. The multivariate-adjusted hazard ratio (HR) of urinary tract cancer between patients receiving thiopurines and those not receiving thiopurines was 2.82 (95% CI: 1.04-7.68, P = 0.04). Other significant risk factors were male gender (HR: 3.98, 95% CI: 1.12-14.10, P = 0.03) and increasing age (HR after 65 years (ref <50): 13.26, 95% CI: 3.52-50.03, P = 0.0001). Conclusion Patients with IBD receiving thiopurines have an increased risk of urinary tract cancers. Clinically relevant excess risk is observed in older men.
- Subjects
URINARY tract infections; INFLAMMATORY bowel disease treatment; INFLAMMATION treatment; INFLAMMATORY bowel diseases; INFLAMMATION; PATIENTS; DISEASE risk factors
- Publication
Alimentary Pharmacology & Therapeutics, 2016, Vol 43, Issue 2, p252
- ISSN
0269-2813
- Publication type
Article
- DOI
10.1111/apt.13466